A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL)

European Journal of Cancer

Volumn 44, Issue 9, 2008, Pages 1269-1274

  Harland, Mark ^a   Goldstein, Alisa M ^b   Kukalizch, Kairen ^a   Taylor, Claire ^c   Hogg, David ^d   Puig, Susana ^e   Badenas, Celia ^e   Gruis, Nelleke ^f   ter Huurne, Jeanet ^f   Bergman, Wilma ^f   Hayward, Nicholas K ^g   Stark, Mitchell ^g   Tsao, Hensin ^h   Tucker, Margaret A ^b   Landi, Maria Teresa ^b   Scarra, Giovanna Bianchi ⁱ   Ghiorzo, Paola ⁱ   Kanetsky, Peter A ^j   Elder, David ^j   Mann, Graham J ^k   Holland, Elizabeth A ^k   Bishop, D Timothy ^a   Newton Bishop, Julia ^a   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

^e HOSPITAL CLÍNIC   (Spain)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Audit; CDKN2A; DHPLC; False negative; Melanoma; Mutation detection; Polymorphism; Sequencing

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; MELANOMA; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MELANOMA; POLYMORPHISM, GENETIC; SKIN NEOPLASMS;

EID: 44649094516     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.03.005     Document Type: Article

References (37)

1. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., and Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 (1994) 753-756
2. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat Genet 8 (1994) 15-21
3. Kamb A., Shattuck-Eidens D., Eeles R., et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8 (1994) 23-26
4. Liu L., Dilworth D., Gao L., et al. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21 (1999) 128-132
5. Harland M., Holland E.A., Ghiorzo P., et al. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 28 (2000) 45-57
6. Harland M., Mistry S., Bishop D.T., and Newton Bishop J.A. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10 (2001) 2679-2686
7. Harland M., Taylor C.F., Bass S., et al. Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. Genes Chromosome Cancer 43 (2005) 128-136
8. Randerson-Moor J.A., Harland M., Williams S., et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10 (2001) 55-62
9. Rizos H., Puig S., Badenas C., et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20 (2001) 5543-5547
10. Hewitt C., Lee Wu C., Evans G., et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 11 (2002) 1273-1279
11. Harland M., Taylor C.F., Chambers P.A., et al. A mutation hotspot at the p14ARF splice site. Oncogene 24 (2005) 4604-4608
12. Mistry S., Tayor C.F., Randerson-Moor J., et al. The prevalence of 9p21 deletions in UK melanoma families. Genes Chromosome Cancer 44 (2005) 292-300
13. Goldstein A.M., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 66 (2006) 9818-9828
14. Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44 (2007) 99-106
15. Mantelli M., Barile M., Ciotti P., et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107 (2002) 214-221
16. Ruiz A., Puig S., Malvehy J., et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 36 (1999) 490-493
17. Holland E.A., Schmid H., Kefford R.F., and Mann G.J. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosome Cancer 25 (1999) 339-348
18. Gillanders E., Hank Juo S.H., Holland E.A., et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 73 (2003) 301-313
19. Bishop D.T., Demenais F., Goldstein A.M., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94 (2002) 894-903
20. Zuo L., Weger J., Yang Q., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12 (1996) 97-99
21. Harland M., Meloni R., Gruis N., et al. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6 (1997) 2061-2067
22. Newton Bishop J.A., Harland M., and Bishop D.T. The genetics of melanoma: the UK experience. Clin Exp Dermatol 23 (1998) 158-161
23. Jones A.C., Austin J., Hansen N., et al. Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin Chem 45 (1999) 1133-1140
24. Liu W., Smith D.I., Rechtzigel K.J., Thibodeau S.N., and James C.D. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res 26 (1998) 1396-1400
25. Orlow I., Roy P., Barz A., Canchola R., Song Y., and Berwick M. Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations. J Mol Diag 3 (2001) 158-163
26. Frueh F.W., and Noyer-Weidner M. The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics. Clin Chem Lab Med 41 (2003) 452-461
27. Herbert O., Trossaert M., Boisseau P., Fressinaud E., and Gerson F. Evaluation of denaturing high-performance liquid chromatography (DHPLC) in the screening of mutations in hemophilia B patients. J Thromb Haemost 2 (2004) 2267-2269
28. Gross E., Arnold N., Goette J., Schwarz-Boeger U., and Kiechle M. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 105 (1999) 72-78
29. Ellis L.A., Taylor C.F., and Taylor G.R. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum Mutat 15 (2000) 556-564
30. van der Heiden I.P., van der Werf M., Lindemans J., and van Schaik R.H. Sequencing: not always the "gold standard". Clin Chem 50 (2004) 248-249
31. Platz A., Hansson J., and Ringborg U. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 78 (1998) 13-15
32. Newton Bishop J.A., Harland M., Bennett D.C., et al. Mutation testing in melanoma families: INK4A, CDK4 and INK4D. Br J Cancer 80 (1999) 295-300
33. Soufir N., Lacapere J.J., Bertrand G., et al. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. Br J Cancer 90 (2004) 503-509
34. Ruas M., and Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378 (1998) F115-F177
35. Parry D., and Peters G. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16 (1996) 3844-3852
36. Cotton R.G. Mutation detection and mutation databases. Clin Chem Lab Med 36 (1998) 519-522
37. Sevilla C., Moatti J.P., Julian-Reynier C., et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 10 (2002) 599-606